Scarica l'app Stockscreener
4.78
10.15%
-0.54
Dopo l'orario di chiusura:
4.78
Kyverna Therapeutics Inc Borsa (KYTX) Ultime notizie
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Short Interest Up 9.7% in October - MarketBeat
(KYTX) Trading Report - Stock Traders Daily
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Shares Purchased by Novo Holdings A S - MarketBeat
Kyverna Therapeutics to Participate in Upcoming September Invest - GuruFocus.com
Gene Therapy Clinical Trial Pipeline Gains Momentum: 180+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - GlobeNewswire Inc.
Kyverna Therapeutics Appoints Mert Aktar to its Board of Directors - cnhinews.com
Kyverna Therapeutics (KYTX): Leading Nano Cap with Promising CAR T-Cell Therapy - Insider Monkey
(KYTX) Technical Data - Stock Traders Daily
500: Something went wrong - Investing.com
JPMorgan bullish on Kyverna Therapeutics stock amid CAR-T expansion potential - Investing.com UK
7 Best Nano Cap Stocks To Invest In - Insider Monkey
The Kyverna Therapeutics Inc. (KYTX) had a good session last reading, didn’t it? - US Post News
Kyverna Therapeutics Inc. (KYTX) Stock: Navigating Market Highs and Lows in 52 Weeks - The InvestChronicle
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Shares Sold by Marshall Wace LLP - MarketBeat
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives $28.71 Consensus Price Target from Analysts - Defense World
Kyverna, Cabaletta started at buys by UBS on CAR T therapy potential - MSN
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives $28.71 Consensus Target Price from Analysts - MarketBeat
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Shares Bought by Millennium Management LLC - MarketBeat
Buy rating assigned to Kyverna Therapeutics stock as analyst notes promising therapy data - Investing.com
Down rounds don’t aid post-IPO performance - BioCentury
JPMorgan Chase & Co's Strategic Acquisition in Kyverna Therapeutics Inc - GuruFocus.com
Kyverna, Cabaletta started at buys by UBS on CAR T therapy potential (NASDAQ:KYTX) - Seeking Alpha
Buy rating assigned to Kyverna Therapeutics stock as analyst notes promising therapy data By Investing.com - Investing.com South Africa
Kyverna Therapeutics (NASDAQ:KYTX) Research Coverage Started at UBS Group - MarketBeat
Kyverna Therapeutics (NASDAQ:KYTX) Lifted to Strong-Buy at RODMAN&RENSHAW - MarketBeat
Kyverna Therapeutics (NASDAQ:KYTX) Coverage Initiated by Analysts at Rodman & Renshaw - MarketBeat
Market Update: Kyverna Therapeutics Inc. (KYTX) Sees Negative Movement, Closing at 4.89 - The Dwinnex
Novo Holdings A S Acquires 1,050,000 Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - MarketBeat
Biotech Kyverna Surges 36% in Debut After Boosting IPO Size - MSN
MBB Public Markets I LLC Acquires New Stake in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - MarketBeat
Deerfield Management Company L.P. Series C Acquires 520,663 Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - MarketBeat
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Shares Purchased by Deerfield Management Company L.P. Series C - MarketBeat
Skandinaviska Enskilda Banken AB publ Acquires 9,385 Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - Defense World
Affinity Asset Advisors LLC Buys Shares of 200,000 Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - MarketBeat
Affinity Asset Advisors LLC Takes $1.50 Million Position in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - Defense World
Bank of New York Mellon Corp Purchases Shares of 55,790 Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - Defense World
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Shares Acquired by Great Point Partners LLC - Defense World
Great Point Partners LLC Increases Stock Holdings in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - MarketBeat
A Tale of Resilience: Kyverna Therapeutics Inc. Amid Stock Market Turbulence - The InvestChronicle
XTX Topco Ltd Acquires Shares of 83,286 Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - Defense World
ECTRIMS 2024: Driving a fast CAR on the MS road and beyond - BioWorld Online
Market Momentum Report: Kyverna Therapeutics Inc. (KYTX)’s Negative Close at 6.39 - The Dwinnex
2 Kite vets fly over to Kyverna Therapeutics—Chutes & Ladders - Fierce Biotech
Kyverna Therapeutics (NASDAQ:KYTX) Rating Reiterated by HC Wainwright - MarketBeat
Kyverna Therapeutics stock maintains Neutral rating from H.C. Wainwright - Investing.com
Kyverna Therapeutics’ (KYTX) Neutral Rating Reiterated at HC Wainwright - Defense World
The Escalator: Imre, Kyverna Therapeutics, The Bloc and more - MM+M Online
Analysts Set Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Target Price at $34.40 - Defense World
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Short Interest Update - Defense World
Kyverna Therapeutics Presents Patient Data Reinforcing Potential of KYV-101 for Treatment of Neuroinflammatory Diseases in Symposium at ECTRIMS 2024 - PR Newswire
E Fund Management Co. Ltd. Invests $1.42 Million in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - MarketBeat
Kyverna Therapeutics Presents Patient Data Reinforcing Potential - GuruFocus.com
Closing Strong: Kyverna Therapeutics Inc. (KYTX) Ends at 6.89, Down -4.31 from Last Close - The Dwinnex
Kyverna Therapeutics names new CEO and board member By Investing.com - Investing.com Canada
Peter Maag resigns as Kyverna CEO - BioCentury
CEO exits from company with 2nd-largest biotech IPO this year - The Business Journals
Kyverna swaps CEOs, leaning on Kite veterans to lead ‘next chapter’ - BioPharma Dive
TD Asset Management Inc Acquires Shares of 90,242 Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - MarketBeat
Kyverna Therapeutics Names Biddle CEO as Maag Resigns - MarketWatch
90,242 Shares in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Purchased by TD Asset Management Inc - Defense World
Kyverna Therapeutics Appoints New CEO - Contract Pharma
1.11%
0.26%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):